Start-Up Previews (9/02)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Cancer Therapeutics, feature Cyclis Pharmaceuticals Inc., Mojave Therapeutics Inc., OncoGeneX Technologies Inc. and Oncologic Inc. Plus these selected Start-Ups across Health Care: CardiacAssist Inc., PharMetrics Inc., Sleep Solutions Inc. and Xoft microTube Inc.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.
During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn
IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.